

APPENDIX 3Y – CHANGE IN DIRECTOR’S INTERESTS

Brisbane, Australia and Delaware, United States, 18 April 2018: Invion Limited (ASX: IVX, “Company”) advises that Dr Mitchell Glass, an Executive Director of the Company, has sold a total of 10,000,000 Invion Limited ordinary shares on-market, on 13, 16 and 17 April 2018.

The sale of these shares by Dr Glass was for personal reasons related to taxation.

Dr Glass currently has no intention of selling further shares in the Company in the immediate future.

An Appendix 3Y accompanies this announcement.

Investor enquiries

Managing Director & CEO, Dr Greg Collier

T: +61 3 9081 6005

E: investor@inviongroup.com

About Invion

Invion is a clinical-stage life-sciences company that holds the license to the next-generation Photo Dynamic Therapy (PDT), Photosoft™. Photosoft™ is a new generation photosensitiser derived from chlorophyll which is hypothesised to identify and selectively accumulate within solid cancerous tumour tissues. Photosoft™ is activated at multiple light sensitivity ranges across a broad spectrum, and therefore has potential to be targeted to both surface and deep seated tumours. Invion has an agreement with The Cho Group to conduct clinical development of Photosoft™ globally, leveraging the Company’s expertise. The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset. Invion has also been granted exclusivity in Australia and New Zealand to commercialise and distribute Photosoft™ for the treatment of cancers. Invion is listed on ASX (ASX:IVX).

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	INVION LIMITED
ABN	76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DR MITCHELL GLASS
Date of last notice	22 November 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	13, 16 and 17 April 2018
No. of securities held prior to change	18,706,932 fully paid Ordinary Shares 8,812,500 Share Options with an exercise price of \$0.12 and an expiry date of 9 November 2018.
Class	Fully Paid Ordinary Shares
Number acquired	Nil
Number disposed	10,000,000 fully paid Ordinary Shares
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$339,465.24

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	8,706,932 fully paid Ordinary Shares 8,812,500 Share Options with an exercise price of \$0.12 and an expiry date of 9 November 2018.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market trades on 13, 16 and 17 April 2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

+ See chapter 19 for defined terms.